A Phase 1 Trial for Evaluation of the Safety, Pharmacokinetics, and [18F] Radiation Dosimetry of CTT1057, a Small Molecule Inhibitor of Prostate Specific Membrane Antigen (PSMA)
Phase of Trial: Phase I
Latest Information Update: 09 Nov 2017
At a glance
- Drugs 18F-CTT 1057 (Primary)
- Indications Prostate cancer
- Focus Adverse reactions; First in man
- Sponsors Cancer Targeted Technology
- 01 Nov 2017 Status changed from recruiting to completed.
- 06 Jun 2017 Results (n=5) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 12 Dec 2016 According to Cancer Targeted Technology media release,this trial is expected to conclude in mid 2017.